Manufacturers report positive phase 3 data for zuranolone for major depressive disorder

In the WATERFALL study, this oral modulator of the GABA-A receptor which is given as a once a day two week course, was found to improve depressive symptoms on the Hamilton Depression Rating Scale to a greater extent than placebo at day 15 (-14.1 vs -12.3, p=0.0141).

Source:

Biospace Inc.